Last edition
News about "Takeda "
Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan
HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.
Takeda | 31/12/2024 | By Aishwarya
Lupin and Takeda to Commercialize Vonoprazan in India
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.
Takeda | 19/09/2024 | By Aishwarya | 151
Mankind Pharma Signs License Deal with Takeda to Commercialise Acidity Drug in India
Mankind Pharma has signed a non-exclusive patent licence agreement with Takeda Pharmaceuticals for commercialising acidity drug Vonoprazan in the Indian market.
Takeda | 22/07/2024 | By Aishwarya | 121
Takeda Signs Option Deal with Ascentage Pharma to Get Exclusive Global License for Olverembatinib
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor.
Takeda | 15/06/2024 | By Aishwarya | 121
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy